{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:36:13Z","timestamp":1785551773436,"version":"3.56.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.cld.2022.01.009","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T07:28:18Z","timestamp":1648798098000},"page":"229-243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Polycystic Kidney\/Liver Disease"],"prefix":"10.1016","volume":"26","author":[{"given":"Rebecca","family":"Roediger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Dieterich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramodh","family":"Chanumolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2022.01.009_bib1","series-title":"StatPearls [Internet]","article-title":"Polycystic Liver Disease. [Updated 2021 May 19]","author":"Kothadia","year":"2021"},{"issue":"6","key":"10.1016\/j.cld.2022.01.009_bib2","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/hep.1840110619","article-title":"Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease","volume":"11","author":"Gabow","year":"1990","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2022.01.009_bib3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1053\/j.ackd.2009.12.005","article-title":"Isolated polycystic liver disease","volume":"17","author":"Qian","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"issue":"6","key":"10.1016\/j.cld.2022.01.009_bib4","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0272-6386(83)80044-4","article-title":"Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935\u20131980","volume":"2","author":"Garcia Iglesias","year":"1983","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.cld.2022.01.009_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2215\/CJN.00080605","article-title":"Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort","volume":"1","author":"Bae","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.cld.2022.01.009_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1399-0004.1986.tb00565.x","article-title":"Adult polycystic liver and kidney diseases are separate entities","volume":"30","author":"Karhunen","year":"1986","journal-title":"Clin Genet"},{"issue":"1","key":"10.1016\/j.cld.2022.01.009_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1681\/ASN.2017050483","article-title":"Genetic complexity of autosomal dominant polycystic kidney and liver diseases","volume":"29","author":"Cornec-Le Gall","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.cld.2022.01.009_bib8","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1 mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le Gall","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.cld.2022.01.009_bib9","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1681\/ASN.2015050583","article-title":"Predicted mutation Strength of Nontruncating PKD1 mutations Aids genotype-phenotype Correlations in autosomal dominant polycystic kidney disease","volume":"27","author":"Heyer","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.cld.2022.01.009_bib10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ki.2009.128","article-title":"Autosomal dominant polycystic kidney disease: the last 3 years","volume":"76","author":"Torres","year":"2009","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.cld.2022.01.009_bib11","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","article-title":"Mutations in GANAB, encoding the glucosidase II\u03b1 Subunit, cause autosomal-dominant polycystic kidney and liver disease","volume":"98","author":"Porath","year":"2016","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1016\/j.cld.2022.01.009_bib12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ng1104","article-title":"Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease","volume":"33","author":"Drenth","year":"2003","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.cld.2022.01.009_bib13","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/ng1357","article-title":"Mutations in SEC63 cause autosomal dominant polycystic liver disease","volume":"36","author":"Davila","year":"2004","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.cld.2022.01.009_bib14","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1172\/JCI96729","article-title":"Isolated polycystic liver disease genes define effectors of polycystin-1 function","volume":"127","author":"Besse","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.cld.2022.01.009_bib15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/75981","article-title":"Mutations of PKD1 in ADPKD2 cysts suggest a pathogenic effect of trans-heterozygous mutations","volume":"25","author":"Watnick","year":"2000","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.cld.2022.01.009_bib16","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0092-8674(00)81793-6","article-title":"The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I","volume":"87","author":"Qian","year":"1996","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.cld.2022.01.009_bib17","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1681\/ASN.V1071524","article-title":"Somatic PKD2 mutations in individual kidney and liver cysts Support a \u201cTwo-Hit\u201d model of cystogenesis in type 2 autosomal dominant polycystic kidney disease","volume":"10","author":"Pei","year":"1999","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.cld.2022.01.009_bib18","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1172\/JCI64313","article-title":"Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity","volume":"122","author":"Hopp","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.cld.2022.01.009_bib19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/ng0695-151","article-title":"The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains","volume":"10","author":"Hughes","year":"1995","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.cld.2022.01.009_bib20","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.cell.2016.09.048","article-title":"The structure of the polycystic kidney disease channel PKD2 in Lipid Nanodiscs","volume":"167","author":"Shen","year":"2016","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.cld.2022.01.009_bib21","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bbadis.2011.02.008","article-title":"Cilium, centrosome and cell cycle regulation in polycystic kidney disease","volume":"1812","author":"Lee","year":"2011","journal-title":"Biochim Biophys Acta - Mol Basis Dis"},{"issue":"1","key":"10.1016\/j.cld.2022.01.009_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/ng1701","article-title":"Defective planar cell polarity in polycystic kidney disease","volume":"38","author":"Fischer","year":"2005","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.cld.2022.01.009_bib23","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.bbadis.2011.03.003","article-title":"Polycystins, focal adhesions and extracellular matrix interactions","volume":"1812","author":"Drummond","year":"2011","journal-title":"Biochim Biophys Acta - Mol Basis Dis"},{"issue":"3","key":"10.1016\/j.cld.2022.01.009_bib24","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","article-title":"Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells","volume":"66","author":"Belibi","year":"2004","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.cld.2022.01.009_bib25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/ndt\/gfy297","article-title":"Pro: tolvaptan delays the progression of autosomal dominant polycystic kidney disease","volume":"34","author":"Torres","year":"2019","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"10.1016\/j.cld.2022.01.009_bib26","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1046\/j.1523-1755.2003.00023.x","article-title":"Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys","volume":"63","author":"Yamaguchi","year":"2003","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.cld.2022.01.009_bib27","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/jhep.2003.50006","article-title":"Clinical profile of autosomal dominant polycystic liver disease","volume":"37","author":"Qian","year":"2003","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2022.01.009_bib28","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/ki.1989.38","article-title":"The clinical utility of renal concentrating capacity in polycystic kidney disease","volume":"35","author":"Gabow","year":"1989","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.cld.2022.01.009_bib29","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0272-6386(12)80541-5","article-title":"Clinical Profiles of Gross hematuria in autosomal dominant polycystic kidney disease","volume":"20","author":"Gabow","year":"1992","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"10.1016\/j.cld.2022.01.009_bib30","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1681\/ASN.V8101560","article-title":"Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease","volume":"8","author":"Johnson","year":"1997","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.cld.2022.01.009_bib31","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0272-6386(12)80922-X","article-title":"Renal stone disease in autosomal dominant polycystic kidney disease","volume":"22","author":"Torres","year":"1993","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.cld.2022.01.009_bib32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/ajkd.2000.8266","article-title":"Anatomic and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease","volume":"36","author":"Grampsas","year":"2000","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"10.1016\/j.cld.2022.01.009_bib33","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S1470-2045(16)30250-9","article-title":"Risk of cancer in patients with polycystic kidney disease: a propensity-score matched analysis of a nationwide, population-based cohort study","volume":"17","author":"Yu","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.cld.2022.01.009_bib34","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1681\/ASN.2013101122","article-title":"Polycystic kidney disease and cancer after renal transplantation","volume":"25","author":"Wetmore","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.cld.2022.01.009_bib35","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1681\/ASN.V491661","article-title":"Renal cell Carcinoma in autosomal dominant polycystic kidney disease","volume":"4","author":"Keith","year":"1994","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"14","key":"10.1016\/j.cld.2022.01.009_bib36","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","article-title":"Autosomal dominant polycystic kidney disease","volume":"359","author":"Grantham","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.cld.2022.01.009_bib37","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/ki.2011.411","article-title":"The HALT polycystic kidney disease trials \u2013 analysis of baseline parameters","volume":"81","author":"Torres","year":"2013","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.cld.2022.01.009_bib38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","article-title":"Polycystic kidney disease","volume":"4","author":"Bergmann","year":"2018","journal-title":"Nat Rev Dis Prim"},{"issue":"6","key":"10.1016\/j.cld.2022.01.009_bib39","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/ndt\/gfw008","article-title":"Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease","volume":"31","author":"Chebib","year":"2016","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"10.1016\/j.cld.2022.01.009_bib40","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1478-3231.2010.02247.x","article-title":"Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases","volume":"31","author":"Van Keimpema","year":"2011","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.cld.2022.01.009_bib41","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jhep.2017.11.024","article-title":"Clinical management of polycystic liver disease","volume":"68","author":"van Aerts","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"35","key":"10.1016\/j.cld.2022.01.009_bib42","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.3748\/wjg.v19.i35.5775","article-title":"Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases","volume":"19","author":"Abu-Wasel","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2022.01.009_bib43","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/hep.29582","article-title":"Polycystic liver disease: hepatic venous outflow obstruction lesions of the noncystic parenchyma have major consequences","volume":"68","author":"Barbier","year":"2018","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.cld.2022.01.009_bib44","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nrneph.2015.128","article-title":"Vascular complications in autosomal dominant polycystic kidney disease","volume":"11","author":"Perrone","year":"2015","journal-title":"Nat Rev Nephrol"},{"issue":"13","key":"10.1016\/j.cld.2022.01.009_bib45","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1056\/NEJM199209243271303","article-title":"Intracranial aneurysms in autosomal dominant polycystic kidney disease","volume":"327","author":"Chapman","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.cld.2022.01.009_bib46","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/j.1523-1755.2004.00572.x","article-title":"Follow-up of intracranial aneurysms in autosomal-dominant polycystic kidney disease","volume":"65","author":"Gibbs","year":"2004","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.cld.2022.01.009_bib47","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1681\/ASN.2008050507","article-title":"Unified criteria for Ultrasonographic diagnosis of ADPKD","volume":"20","author":"Pei","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"20","key":"10.1016\/j.cld.2022.01.009_bib48","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.cld.2022.01.009_bib49","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00000658-199703000-00008","article-title":"Adult polycystic liver disease: is fenestration the most adequate operation for long-term management?","volume":"225","author":"Gigot","year":"1997","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.cld.2022.01.009_bib50","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/SLA.0b013e3181ad83dc","article-title":"Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation","volume":"250","author":"Schnelldorfer","year":"2009","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.cld.2022.01.009_bib51","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.ajkd.2020.12.020","article-title":"Assessing risk of rapid progression in autosomal dominant polycystic kidney disease and special Considerations for disease-modifying therapy","volume":"78","author":"Chebib","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.cld.2022.01.009_bib52","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for Selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.cld.2022.01.009_bib53","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1053\/j.ajkd.2017.01.046","article-title":"PKD2-Related autosomal dominant polycystic kidney disease: prevalence, clinical presentation, mutation spectrum, and Prognosis","volume":"70","author":"Cornec-Le Gall","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"10.1016\/j.cld.2022.01.009_bib54","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.cld.2022.01.009_bib55","doi-asserted-by":"crossref","first-page":"F261","DOI":"10.1152\/ajprenal.00345.2014","article-title":"Effects of hydration in rats and mice with polycystic kidney disease","volume":"308","author":"Hopp","year":"2015","journal-title":"Am J Physiol - Ren Physiol"},{"issue":"25","key":"10.1016\/j.cld.2022.01.009_bib56","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.cld.2022.01.009_bib57","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.cld.2022.01.009_bib58","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.ekir.2017.07.004","article-title":"Tolerability of aquaretic-related symptoms following tolvaptan for autosomal dominant polycystic kidney disease: results from TEMPO 3:4","volume":"2","author":"Devuyst","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1016\/j.cld.2022.01.009_bib59","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000477664","article-title":"Tolvaptan for the treatment of enlarged polycystic liver disease","volume":"7","author":"Mizuno","year":"2017","journal-title":"Case Rep Nephrol Dial"},{"issue":"24","key":"10.1016\/j.cld.2022.01.009_bib60","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.cld.2022.01.009_bib61","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneph.2014.104","article-title":"Renal transplantation in autosomal dominant polycystic kidney disease","volume":"10","author":"Kanaan","year":"2014","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"10.1016\/j.cld.2022.01.009_bib62","doi-asserted-by":"crossref","first-page":"950","DOI":"10.2174\/1389450116666150427161743","article-title":"Therapeutic targets in polycystic liver disease","volume":"18","author":"Masyuk","year":"2018","journal-title":"Curr Drug Targets"},{"issue":"3","key":"10.1016\/j.cld.2022.01.009_bib63","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","article-title":"Octreotide inhibits hepatic cystogenesis in a Rodent model of polycystic liver disease by reducing cholangiocyte Adenosine 3\u2032,5\u2032-cyclic Monophosphate","volume":"132","author":"Masyuk","year":"2007","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2022.01.009_bib64","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1308\/rcsann.2016.0023","article-title":"Medical therapy for polycystic liver disease","volume":"98","author":"Khan","year":"2016","journal-title":"Ann R Coll Surg Engl"},{"issue":"4","key":"10.1016\/j.cld.2022.01.009_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002777","article-title":"Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): a randomized, double-blind, placebo-controlled, multicenter trial","volume":"16","author":"Perico","year":"2019","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.cld.2022.01.009_bib66","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2015.05.023","article-title":"Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease","volume":"63","author":"Munoz-Garrido","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2022.01.009_bib67","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jhep.2016.05.009","article-title":"Ursodeoxycholic acid in advanced polycystic liver disease: a phase 2 multicenter randomized controlled trial","volume":"65","author":"D\u2019Agnolo","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2022.01.009_bib68","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1053\/j.ackd.2010.01.003","article-title":"Extrarenal manifestations of autosomal dominant polycystic kidney disease","volume":"17","author":"Pirson","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"issue":"1","key":"10.1016\/j.cld.2022.01.009_bib69","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2214\/AJR.16.16130","article-title":"Efficacy and safety of aspiration sclerotherapy of simple hepatic cysts: a systematic review","volume":"208","author":"Wijnands","year":"2017","journal-title":"Am J Roentgenol"},{"issue":"6","key":"10.1016\/j.cld.2022.01.009_bib70","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1053\/j.ajkd.2014.01.422","article-title":"Intravascular embolization therapy in patients with enlarged polycystic liver","volume":"63","author":"Hoshino","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"16","key":"10.1016\/j.cld.2022.01.009_bib71","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.4103\/0366-6999.211882","article-title":"Transarterial embolization for treatment of symptomatic polycystic liver disease: more than 2-year follow-up","volume":"130","author":"Zhang","year":"2017","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"10.1016\/j.cld.2022.01.009_bib72","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/hepr.12560","article-title":"Comparison of volume-reductive therapies for massive polycystic liver disease in autosomal dominant polycystic kidney disease","volume":"46","author":"Yang","year":"2016","journal-title":"Hepatol Res"},{"issue":"3","key":"10.1016\/j.cld.2022.01.009_bib73","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00464-018-6490-8","article-title":"Clinical response after laparoscopic fenestration of symptomatic hepatic cysts: a systematic review and meta-analysis","volume":"33","author":"Bernts","year":"2019","journal-title":"Surg Endosc"},{"key":"10.1016\/j.cld.2022.01.009_bib74","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0016-5085(95)90078-0","article-title":"Liver resection and cyst fenestration in the treatment of severe polycystic liver disease","volume":"108","author":"Que","year":"1995","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.cld.2022.01.009_bib75","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1432-2277.2011.01360.x","article-title":"Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study","volume":"24","author":"Van Keimpema","year":"2011","journal-title":"Transpl Int"},{"key":"10.1016\/j.cld.2022.01.009_bib76","series-title":"Guidance to liver transplant Programs and the National liver review board for: Adult MELD exception review. Organ Procurement and transplant Network","year":"2021"},{"issue":"8","key":"10.1016\/j.cld.2022.01.009_bib77","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1097\/TP.0000000000001711","article-title":"Waitlisted candidates with polycystic liver disease are more likely to be transplanted than those with chronic liver failure","volume":"101","author":"Doshi","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.cld.2022.01.009_bib78","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/lt.20780","article-title":"Outcome and quality of life in patients with polycystic liver disease after liver or Combined liver-kidney transplantation","volume":"122","author":"Kirchner","year":"2006","journal-title":"Liver Transpl"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326122000095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326122000095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:58:22Z","timestamp":1761069502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326122000095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1089326122000095"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2022.01.009","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polycystic Kidney\/Liver Disease","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2022.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}